TY - JOUR
T1 - Preventive and Therapeutic Effect of Metformin in Head and Neck Cancer
T2 - A Concise Review
AU - Bouland, Cyril
AU - Vanden Eynden, Xavier
AU - Lalmand, Martin
AU - Buset, Thibaut
AU - Yanni, Antoine
AU - Javadian, Rokneddine
AU - Rodriguez, Alexandra
AU - Loeb, Isabelle
AU - Lechien, Jérôme R.
AU - Journe, Fabrice
AU - Saussez, Sven
AU - Dequanter, Didier
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/10/1
Y1 - 2023/10/1
N2 - Background: Head and neck cancer (HNC) is a complex affection. Nowadays, conventional treatments are associated with many side effects, reducing the patient’s quality of life. Recent studies suggest that metformin, a first-line treatment for diabetes, could decrease cancer incidence and improve cancer-related survival rates. Methods: This systematic review summarizes important data from studies evaluating metformin’s contribution to preventing and treating HNC. Results: The results suggest a protective effect of metformin in HNC. However, no consensus has been found on its therapeutic effects. Metformin seems to confer an improved cancer-related survival rate in a diabetic population, but compared to a non-diabetic population, the review could not identify any advantages. Nevertheless, no studies presented a negative impact. Conclusion: In conclusion, the results of this systematic review suggest that HNC patients may benefit from metformin. Indeed, it would reduce the HNC incidence. However, more studies are required to evaluate the effect on cancer-related survival rates.
AB - Background: Head and neck cancer (HNC) is a complex affection. Nowadays, conventional treatments are associated with many side effects, reducing the patient’s quality of life. Recent studies suggest that metformin, a first-line treatment for diabetes, could decrease cancer incidence and improve cancer-related survival rates. Methods: This systematic review summarizes important data from studies evaluating metformin’s contribution to preventing and treating HNC. Results: The results suggest a protective effect of metformin in HNC. However, no consensus has been found on its therapeutic effects. Metformin seems to confer an improved cancer-related survival rate in a diabetic population, but compared to a non-diabetic population, the review could not identify any advantages. Nevertheless, no studies presented a negative impact. Conclusion: In conclusion, the results of this systematic review suggest that HNC patients may benefit from metformin. Indeed, it would reduce the HNC incidence. However, more studies are required to evaluate the effect on cancer-related survival rates.
KW - head and neck cancer
KW - metformin
KW - prevention
KW - systematic review
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85173815486&partnerID=8YFLogxK
U2 - 10.3390/jcm12196195
DO - 10.3390/jcm12196195
M3 - Review article
AN - SCOPUS:85173815486
SN - 2077-0383
VL - 12
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 19
M1 - 6195
ER -